Therapeutic treatment with phosphodiesterase-4 inhibitors alleviates kidney injury and renal fibrosis by increasing MMP-9 in a doxorubicin-induced nephrotoxicity mouse model

Walyson Coelho Costa,Vinícius Amorim Beltrami,Gabriel Henrique Campolina-Silva,Celso Martins Queiroz-Junior,Rodrigo M Florentino, Jéssica Rayssa Machado,Débora Gonzaga Martins,William Antonio Gonçalves,Lívia Corrêa Barroso,Katia Michelle Freitas,Fernando Pedro de Souza-Neto,Franciel Batista Félix,Rafaela Fernandes da Silva,Cleida Aparecida Oliveira,Niels Olsen Saraiva Câmara,Milene Alvarenga Rachid,Mauro Martins Teixeira,Barbara Maximino Rezende,Vanessa Pinho

International Immunopharmacology（2023）

引用 3|浏览13

暂无评分

摘要

•Therapeutic treatment with PDE4 inhibitor ameliorates renal function associated to doxorubicin-induced nephropathy.•Therapeutic treatment with PDE4 inhibitors reverses established inflammation associated to doxorubicin-induced nephropathy.•PDE4 inhibitor induces MMP9 activation and reduces established renal fibrosis.•Roflumilast may be a promising new treatment for the clinical management of nephropathy.

查看译文

关键词

Nephrotic syndrome,Phosphodiesterase-4,Inflammation,Roflumilast,Rolipram,Doxorubicin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要